ArticleHaematologica2024

Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma.

Silvia Marino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.